Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004930 · ClinicalTrials.gov registry record · Phase 1
Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004930: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00004930 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004930, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of inhaled doxorubicin in treating patients who have primary lung cancer or lung metastases.
Interventions
- DRUG doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-07 |
| Est. Completion | 2004-02 |
| Phase | Phase 1 |
What the finished NCT00004930 record still lists
NCT00004930 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which doxorubicin hydrochloride is the first listed.
NCT00004930 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004930 about?
NCT00004930 is a clinical study titled "Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of inhaled doxorubicin in treating patients who have primary lung cancer or lung metastases.
What is the current status of trial NCT00004930?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-07. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00004930?
The interventions under investigation include: doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00004930?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia